Exhibit 99.1 PRELIMINARY NOTE The unaudited interim condensed Consolidated Financial Statements for the three- and nine-month periods ended September 30, 2024, included herein, have been prepared in accordance with International Accounting Standard 34 ("Interim Financial Reporting"), as issued by the International Accounting Standards Board ("IASB"). The Consolidated Financial Statements are presented in euros. All references in this interim report to "$," and "U.S. dollars" mean U.S. dollars and all refere ...

The Company will now target five major cancer types with its four clinically active compounds across both TCR-T cell therapies and TCR-based Bispecifics  Today, Company discloses first clinical data from the TCR Bispecific molecule, TCER® IMA402 targeting PRAME, in the Phase 1 dose escalation trial, demonstrating a favorable tolerability profile and signs of dose-dependent and PRAME expression-dependent clinical activity, including first objective responses in melanoma patients; early pharmacokinetics data ...

The market expects Immatics (IMTX) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended September 2024. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.The earnings report might help the stock move higher if these key numbers are better than expectations. On the other hand, if they ...

Company to host conference call and webcast today, October 10, at 9:00 am EDT/3:00 pm CEST Company announces updated Phase 1b clinical data on ACTengine® IMA203 targeting PRAME in 28 heavily pretreated metastatic melanoma patients with substantially enhanced maturity compared to the last data update in May 2024 and provides the first report on progression-free survival (PFS) and overall survival (OS) Based on the Phase 1b data, the Company will proceed directly to a registration-enabling Phase 3 trial Regul ...

Houston, Texas and Tuebingen, Germany, October 4, 2024 – Immatics N.V. (NASDAQ: IMTX, "Immatics" or the "Company"), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, today announced upcoming oral and poster presentations at the 39th Annual Meeting of the Society for Immunotherapy of Cancer in Houston, Texas from November 6 - 10, 2024. Full abstracts will be available on November 5, 2024, at 9:00 am EST in the JITC Supplement. Ora ...

TCER® IMA401 is a novel, next-generation, half-life extended bispecific T cell engager directed against an HLA-A*02-presented peptide derived from MAGEA4 and MAGEA8 with high target copy numbers on various solid cancers Data from the first-in-human Phase 1 dose escalation trial demonstrate initial anti-tumor activity and a manageable tolerability profile for TCER® IMA401 monotherapy; patient population includes 35 heavily pre-treated patients across 16 different solid tumor types; dose escalation is ongoing ...

Core Insights - Immatics N.V. announced updated clinical data on its lead cell therapy candidate, ACTengine® IMA203, targeting PRAME, to be presented at the 21st International Congress of the Society for Melanoma Research [1] Group 1: Clinical Data Presentation - The oral presentation is scheduled for October 11, 2024, from 8:00 to 8:20 am Central Daylight Time, during the Plenary Session 1 focused on Developmental Immunotherapy [2] - The presentation will be delivered by Dr. Martin Wermke from University Hospital Dresden, Germany, and will provide a clinical update on ACTengine IMA203 TCR-T targeting PRAME in PD1-refractory metastatic melanoma [2] Group 2: About ACTengine IMA203 - ACTengine® IMA203 is an autologous T cell product with a genetically modified TCR directed against a peptide derived from PRAME, which is frequently expressed in various solid cancers [2] - The PRAME peptide is characterized by high copy numbers per tumor cell and is specifically expressed in tumor tissue, indicating its potential for a broad cancer patient population [2] - Immatics utilizes its proprietary mass spectrometry-based target discovery platform, XPRESIDENT®, and TCR discovery and engineering platform, XCEPTOR®, to develop this targeted therapy [2] Group 3: Current Trials - ACTengine® IMA203 is currently being evaluated in a Phase 1 trial as a monotherapy and as a second-generation IMA203CD8 (GEN2) monotherapy, which combines both CD4+ and CD8+ T cells [3] - The combination of IMA203 with an immune checkpoint inhibitor has been deprioritized in the development pipeline [3] Group 4: Company Overview - Immatics focuses on discovering true targets for cancer immunotherapies and developing specific T cell receptors to enable robust T cell responses against these targets [4] - The company aims to deliver the power of T cells and unlock new treatment avenues for cancer patients through its pipeline of Adoptive Cell Therapies and TCR Bispecifics [4]

Immatics (IMTX) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.35. This compares to loss of $0.35 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 48.57%. A quarter ago, it was expected that this company would post a loss of $0.74 per share when it actually produced a loss of $0.04, delivering a surprise of 94.59%. Over the last four quarters, the company has surpassed con ...

Exhibit 99.1 As used in this interim report, the terms "Immatics", "we", "our", "us", "the Group" and "the Company" refer to Immatics N.V. and its subsidiaries, taken as a whole, unless the context otherwise requires. The unaudited interim condensed consolidated financial statements and Management's Discussion & Analysis of Financial Condition and Results of Operations in this interim report are related to Immatics N.V. and its German subsidiary Immatics Biotechnologies GmbH as well as its U.S. subsidiary I ...

Clinical data from May 2024 on ACTengine® IMA203 targeting PRAME in 30 heavily pre-treated metastatic melanoma patients at RP2D: 55% confirmed objective response rate, median duration of response of 13.5 months; IMA203 continues to maintain a favorable tolerability profile Registration-enabling randomized Phase 2/3 trial for ACTengine® IMA203 in 2L+ melanoma planned to commence in 2024 Next data update on IMA203 and IMA203CD8 (GEN2) to be presented at medical conferences in 2H 2024 First Phase 1 dose escala ...